Stockreport

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel...

Ironwood Pharmaceuticals, Inc. - Class A  (IRWD) 
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.ironwoodpharma.com
PDF – Results demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C –– LINZESS U.S. prescribing informa [Read more]